AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2899451
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion at a dose rate of 80 +/- 59 micrograms/kg/min
Trial: 26588810
Drug: Closed-loop (CL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop (CL) therapy with subcutaneous insulin via CL pump (n = 7)
Trial: 26588810
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections with blinded continuous glucose monitor (CGM) (n = 7)
Trial: 19006503
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg daily)
Trial: 17213007
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg (older group)
Trial: 8442620
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours)
Trial: 3620399
Drug: No oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No oxytocin infusion (control)
Trial: 31909811
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS) - 20 g daily during pregnancy and 6 months postpartum; infants received LNS from 6 to 18 months.
Trial: 31909811
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (MMN) - 1 capsule daily during pregnancy and 6 months postpartum; combined with IFA group for analysis.
Trial: 31909811
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA) - 1 capsule daily during pregnancy, then placebo postpartum; combined with MMN group for analysis.
Trial: 12363007
Drug: Overall antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall antimicrobial use among children <7 years old (from 13.6 to 11.1 defined daily dosages/1000 children per day)
Trial: 1704561
Drug: Steroid-tipped leads
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-tipped leads
Trial: 24383602
Drug: Levobupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine plus 1 μg·kg(‐1) dexmedetomidine
Trial: 24383602
Drug: Levobupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine plus 2 μg·kg(‐1) dexmedetomidine
Trial: 19309747
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg modafinil once daily for 4 weeks (Phase 1)
Trial: 16750463
Drug: Sumatriptan 4
RxNorm normalized name: sumatriptan 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 4 mg SC
Trial: 10206720
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACh and VIP
Trial: 10206720
Drug: Cetirizine (H1-antagonist)
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine (H1-antagonist) pretreatment before ACh injection
Trial: 2360502
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 to 800 mg once daily)
Trial: 26044228
Drug: Ultrasound and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound and water capsule-guided local injection of botulinum toxin type A (group B)
Trial: 26044228
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug treatment (group A)
Trial: 23108953
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 (10 mg/kg QW) plus cisplatin/capecitabine (CX)
Trial: 23108953
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 (3 mg/kg QW) plus cisplatin/capecitabine (CX)
Trial: 18672290
Drug: Nilvadipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (2 mg twice daily)
Trial: 17039647
Drug: dexamethasone suspension
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone suspension
Trial: 17039647
Drug: prednisone suspension
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisone suspension
Trial: 17039647
Drug: cherry‐flavored prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cherry‐flavored prednisolone suspensions
Trial: 12694213
Drug: Carriers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carriers of TNFA-308*1/2 (*G/A) genotype
Trial: 9005589
Drug: Mitomycin-C 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C 30 mg for 12 months
Trial: 9005589
Drug: Mitomycin-C 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C 40 mg for 6 months
Trial: 25540035
Drug: Cognitive-behavioral couple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral couple therapy
Trial: 18794543
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and Estramustine (D/E); 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks, plus prednisone (10 mg/d)
Trial: 18794543
Drug: Docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel alone (D); 35 mg/m(2) on days 2 and 9, every 3 weeks, plus prednisone (10 mg/d)
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 400 micrograms (low dose) after placebo
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 1600 micrograms (high dose) after placebo
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 400 micrograms (low dose) after formoterol 12 micrograms
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 1600 micrograms (high dose) after formoterol 12 micrograms
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 400 micrograms (low dose) after salmeterol 50 micrograms
Trial: 10329815
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 1600 micrograms (high dose) after salmeterol 50 micrograms
Trial: 7757335
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin therapy for 12 months
Trial: 2185303
Drug: Amitriptyline 150
RxNorm normalized name: amitriptyline 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 150 mg/d
Trial: 2185303
Drug: Milnacipran 50
RxNorm normalized name: milnacipran 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 50 mg/d
Trial: 7033745
Drug: Active pharmacological
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pharmacological treatment
Trial: 31805992
Drug: Calprotectin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calprotectin levels at DMARD tapering/stopping
Trial: 26455521
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily rosuvastatin
Trial: 23401474
Drug: Silexan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan (160 mg)
Trial: 21617837
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly health information)
Trial: 20396722
Drug: Artrofoon in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artrofoon in combination with SCENAR therapy
Trial: 20396722
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in combination with SCENAR therapy
Trial: 17519319
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml water
Trial: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 1 min
Trial: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 2 min
Trial: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 4 min
Trial: 29641212
Drug: Hippotherapy (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (24 sessions, twice weekly)
Trial: 27543447
Drug: Amiselimod 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiselimod 0.1 mg
Trial: 27543447
Drug: Amiselimod 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiselimod 0.2 mg
Trial: 18762864
Drug: Kefir (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir (oral lavage and 250 ml swallowed)
Trial: 18762864
Drug: 0.09% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% NaCl (oral lavage twice a day)
Trial: 15189747
Drug: LP +
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP + N (Insulin lispro + NPH)
Trial: 3356051
Drug: Acetaminophen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (20 mg.kg‐1 administered rectally)
Trial: 3356051
Drug: Meperidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (1 mg.kg‐1 administered intramuscularly)
Trial: 22206271
Drug: High-energy and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy and high-protein diet (group B, n = 12, 4.2 g/kg/d protein and 150 kcal/kg/d)
Trial: 22206271
Drug: High-energy and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy and high-protein diet (group C, n = 12, 4.7 g/kg/d protein and 150 kcal/kg/d)
Trial: 22206271
Drug: Standard preterm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preterm formula (group A, n = 8, 3.7 g/kg/d protein and 129 kcal/kg/d)
Trial: 356247
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg b.i.d.
Trial: 12072586
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lercanidipine
Trial: 12072586
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lercanidipine
Trial: 10436254
Drug: Low-dose glyburide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glyburide plus metformin (5, 7.5 or 10 mg/day glyburide and 800, 1,200 or 1,600 mg/day metformin)
Trial: 10436254
Drug: High-dose glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glyburide alone (5, 10 or 15 mg/day)
Trial: 10436254
Drug: Low-dose glyburide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glyburide plus metformin
Trial: 8000659
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefotetan preoperatively
Trial: 8000659
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin preoperatively
Trial: 8000659
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin preoperatively followed by three postoperative doses
Trial: 27017895
Drug: Citrulline-malate (CM)
RxNorm normalized name: citrulline malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline-malate (CM) supplementation (12 g dextrose + 8 g CM)
Trial: 27017895
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) (12 g dextrose)
Trial: 23666589
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg IORA vancomycin
Trial: 23666589
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg IORA vancomycin
Trial: 23666589
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g systemic vancomycin
Trial: 23563461
Drug: 0.75% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% hyperbaric ropivacaine + 25 μg (0.5 ml) fentanyl
Trial: 23563461
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg (l ml) hyperbaric bupivacaine + 25 μg (0.5 ml) fentanyl
Trial: 16639341
Drug: ESO 20
RxNorm normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESO 20 mg qd + FPV 1400 mg bid
Trial: 16639341
Drug: ESO 20
RxNorm normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESO 20 mg qd + FPV 700 mg bid + RTV 100 mg bid
Trial: 16639341
Drug: FPV 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 1400 mg bid
Trial: 16639341
Drug: FPV 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 700 mg bid + RTV 100 mg bid
Trial: 12762259
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment during the first hour
Trial: 12762259
Drug: Thrombolytics (third-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytics (third-generation agents like reteplase and tenecteplase)
Trial: 1809524
Drug: 0.4% Sn2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% Sn2 gel used while toothbrushing every day for three months
Trial: 1809524
Drug: 1.1% neutral
RxNorm normalized name: Neutragard 1.1% Neutral Sodium Fluoride Gel (Mint)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% neutral NaF gel for three months followed by twice daily rinsing with a remineralizing mouthrinse
Trial: 28643477
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine polyphenols (RWPs) 600 mg/d
Trial: 26365326
Drug: CEE alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE alone (0.625 mg/d)
Trial: 26365326
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + MPA (0.625 mg/d CEE and 2.5 mg/d MPA)
Trial: 20565840
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with cervical carcinoma (CC)
Trial: 19124372
Drug: Nebulized formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized formoterol fumarate (20 microg) inhalation solution for nebulization (FFIS)
Trial: 19124372
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate dry powder inhalation (12 microg) (FA)
Trial: 15679563
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (n = 216)
Trial: 10556133
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (500 microg twice a day) for 4 weeks
Trial: 8633829
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with slow‐acting antirheumatic drugs (SAARDs)
Trial: 8633829
Drug: Delayed introduction
RxNorm normalized name: INTRODUCTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed introduction of treatment with slow‐acting antirheumatic drugs (SAARDs)
Trial: 1361594
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled beclomethasone dipropionate (BDP) 1500 micrograms/day
Trial: 1361594
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled beclomethasone dipropionate (BDP) 300 micrograms/day
Trial: 1361594
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and low-dose BDP
Trial: 25135805
Drug: Community pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacist intervention discussing patients' beliefs about their medicines
Trial: 12584832
Drug: Yiqi Wenyang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Wenyang Huoxue Lishui (YWHL) treatment
Trial: 7939438
Drug: Alarm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm treatment
Trial: 28002202
Drug: HFM +
RxNorm normalized name: Hydroxyfasudil
DrugBank: Hydroxyfasudil (DB04707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFM + BH4 (5 mg/kg)
Trial: 22086747
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761® (240 mg once daily)
Trial: 19706018
Drug: Dorzolamide/timolol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol combination (DT)
Trial: 1600965
Drug: Milrinone bolus
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone bolus dose (50 micrograms kg‐1) followed by infusion at rates of 0.375, 0.5 or 0.75 microgram kg‐1 min‐1
Trial: 29209510
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion
Trial: 6389233
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion (CONT: 0.4 mU X kg‐1 X min‐1)
Trial: 6389233
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin infusion (PULS: 0.8 mU X kg‐1 X min‐1, 7.5 min of 15)
Trial: 27084832
Drug: Three weekly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weekly IMT sessions (high intensity) for five months
Trial: 17366918
Drug: Preoperative amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative amino acid infusion
Trial: 17366918
Drug: Perioperative amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative amino acid infusion
Trial: 12002412
Drug: Octreotide (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (12 h infusion: bolus 0.75 microg/kg followed by 0.75 microg/kg/h)
Trial: 9735391
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CT group) with low-dose oral UFT and continuous venous 5FU infusion.
Trial: 9735391
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (NCT group), n=28.
Trial: 2109573
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin (single 400‐mg dose)
Trial: 2109573
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone (250‐mg dose)
Trial: 31287556
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate with 200 mL mannitol
Trial: 27621150
Drug: PF-05190457 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05190457 100 mg
Trial: 27621150
Drug: PF-05190457 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05190457 150 mg
Trial: 27621150
Drug: PF-05190457 ≥50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05190457 ≥50 mg
Trial: 24481579
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg iv dexketoprofen trometamol
Trial: 24481579
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg iv paracetamol
Trial: 22162339
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) group program for RA fatigue
Trial: 19074913
Drug: Prednisone 1-4
RxNorm normalized name: prednisone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1-4 mg/day
Trial: 15893008
Drug: PORT (5040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PORT (5040 cGy in 28 daily fractions)
Trial: 15893008
Drug: CPORT (PORT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1‐3) administered concurrently)
Trial: 15893008
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (PORT and CPORT)
Trial: 12139537
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 30 ml with 30 mg ketamine (Group K)
Trial: 12139537
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 30 ml (Group P)
Trial: 12139537
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine with 30 mg ketamine i.v. (Group C)